Clinical Trial Update: A Study of Telitacicept for IgA Nephropathy (TELIGAN) [Phase 3]

View source ↗

Summary

Phase 3 trial update for telitacicept in primary IgA nephropathy; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Telitacicept

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Primary IgA Nephropathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING